<DOC>
	<DOCNO>NCT01325051</DOCNO>
	<brief_summary>The purpose study characterize way first commercially available integrase inhibitor , raltegravir , new class antiretrovirals use treat HIV , distribute rectal mucosal tissue . This information generate important information regard drug 's penetration lymphoid tissue rapidly deplete HIV infection . Subsequently strategies prevent sexual transmission HIV treat HIV-infected individual design .</brief_summary>
	<brief_title>Study Characterize Pharmacokinetics Raltegravir Gastrointestinal ( GI ) Tract Healthy Male Volunteers</brief_title>
	<detailed_description>Participants : 14 HIV-uninfected , healthy , male volunteer , ≥18 ≤49 year age , recruit enrol . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12-lead ECG , clinical laboratory test . Participants race ethnicity consider enrollment . This study conduct single site United States : University North Carolina Chapel Hill . Procedures ( method ) : An outpatient screening visit conduct potential participant obtain informed consent evaluate eligibility . Once enrol , subject take 400 mg oral dose raltegravir twice daily Day 1 Day 7 . The healthy men enrol study undergo single-dose multiple-dose pharmacokinetic sampling . Blood collect via peripheral IV pre-dose , 1 , 2 , 3 , 4 , 6 , 8 12 hour post-dose . Subjects undergo two colonoscopy sample visit ( Day 1 Day 7 ) purpose obtain gastrointestinal-associated lymphoid tissue ( GALT ) . Each subject biopsy obtain one follow time point post-dose : 1 , 2 , 3 , 4 , 6 , 8 , 12 hour . Seven ten day last inpatient sample visit , subject complete follow-up visit .</detailed_description>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . Healthy male subject age 18 49 year , inclusive , intact genital tract gastrointestinal tract . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG , clinical laboratory test . 2 . Body Mass Index ( BMI ) approximately 18 30 kg/m^2 ; total body weight great equal 50 kg ( 110 lb ) . 3 . Evidence personally sign date informed consent document indicate subject inform pertinent aspects trial . 4 . Willing able comply schedule visit , treatment plan , laboratory test , trial procedure . Exclusion Criteria 1 ) medical condition find deemed investigator ineligible</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>raltegravir</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>healthy</keyword>
	<keyword>male</keyword>
	<keyword>volunteer</keyword>
	<keyword>gastrointestinal</keyword>
	<keyword>tract</keyword>
</DOC>